CRIA Update
Table of Contents, Spring 2000

HIV Research 2000: Unanswered Questions

The purpose of our agency's newsletter is to educate and inform. We are certainly not adverse to controversial topics when they provoke wider discussion. For some of our readers this issue of important health care topics will be controversial. In fact, only after much heated discussion could our editorial staff reach consensus on this issue.

We start the issue with a discussion of this most controversial topic: structured treatment interruptions, or drug holidays, by regular contributor Tim Horn. Next, Anne Monroe provides an update on the utility of resistance testing in making treatment decisions. CRIA's own James Learned presents a comprehensive look at the emerging metabolic complications associated with HIV disease and antiretroviral treatment. Last but not least, Richard Jeffreys covers an exciting new area of research on the human thymus and its role in HIV disease.

In response to readers' requests, this issue contains the first installation of a regular new section entitled "New Drugs in Development." This section will focus on drugs in clinical development, review their performance so far, and what we might expect from them in the future. As usual, we hope you will find this issue interesting and informative, remembering that sound health care decisions are always made in consultation with your medical provider.